Metrika članka

  • citati u SCindeksu: [2]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u prethodnih 30 dana:19
  • preuzimanja u prethodnih 30 dana:16
članak: 1 od 28  
Back povratak na rezultate
Medicinski časopis
2014, vol. 48, br. 1, str. 21-27
jezik rada: srpski
vrsta rada: pregledni članak
doi:10.5937/mckg48-4123


Dijastolna srčana slabost kod bolesnika na hemodijalizi - etiopatogeneza, dijagnostika i lečenje
aKlinika za urologiju i nefrologiju, Klinički centar 'Kragujevac', Kragujevac
bKlinika za kardiologiju, Klinički centar 'Kragujevac', Kragujevac
cCentar za alergologiju sa kliničkom imunologijom, Klinički centar 'Kragujevac', Kragujevac

e-adresa: brankicaaa-kg@hotmail.com

Projekat

Analiza strukture troškova i uticaja na zdravstveni budžet Republike Srbije epidemiološki najmasovnijih i/ili najskupljih oboljenja i procena odnosa troškovi / efektivnost / korisnost medicinskih intervencija (MPNTR - 175014)

Sažetak

Bolesti srca su vodeći uzrok smrti bolesnika koji se leče hemodijalizom. Stopa kardiovaskularnog mortaliteta kod ovih bolesnika iznosi približno 9% godišnje, a među kardiovaskularnim komplikacijama najveća je prevalenca hipertrofije leve komore, ishemijske bolesti srca i zastojne srčane slabosti. Rad je imao za cilj da utvrdi faktore kardiovaskularnog rizika, patogenetske mehanizme razvoja poremećaja dijastolne funkcije srca, i da ukaže na klinički značaj ranog otkrivanja i pravovremenog lečenja bolesnika sa poremećajem dijastolne funkcije srca. Analizirani su stručni radovi i kliničke studije koje se bave dijagnostikovanjem i lečenjem poremećaja dijastolne funkcije srca u populaciji bolesnika koji se leče hemodijalizom. Hipertrofiju leve komore ima 75% bolesnika koji se leče hemodijalizom. U faktore rizika za razvoj hipertrofije leve komore kod bolesnika na hemodijalizi spadaju: povećan protok krvi kroz arterio-vensku fistulu, anemija, povećana zapremina vanćelijske tečnosti, hipertenzija, oksidativni stres, mikroinflamacija, hiperhomocisteinemija i sekundarni hiperparatireoidizam. Hipertrofija leve komore je značajan uzrok poremećaja dijastolne funkcije leve komore u ovoj populaciji bolesnika. Dijagnostička strategija za rano otkrivanje bolesnika sa povećanim rizikom za razvoj asimptomatskog poremećaja dijastolne funkcije leve komore treba da uključi: ehokardiografski pregled, testove za dokazivanje koronarne arterijske bolesti, kao i testove za procenu funkcije miokarda. Rano otkrivanje bolesnika sa visokim rizikom za razvoj dijastolne srčane slabosti omogućava pravovremenu primenu odgovarajuće strategije lečenja, koja obezbeđuje visok stepen preživljavanja bolesnika na hemodijalizi.

Ključne reči

Reference

Aurigemma, G.P., Gaasch, W.H. (2004) Diastolic Heart Failure. N Eng J Med, 351(11): 1
Bie, M.K., Dam, B., Gaasbeek, A., Buren, M., Erven, L., Bax, J.J., Schalij, M.J., Rabelink, T.J., Jukema, W.J. (2009) The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. Eur Heart J, 30(13): 1559-64
Chan, C.T., Levin, N.W., Chertow, G.M., Larive, B., Schulman, G., Kotanko, P. (2010) Determinants of cardiac autonomic dysfunction in ESRD. Clin J Am Soc Nephrol, 5(10): 1821-7
Cice, G., Ferrara, L., di Benedetto, A., Russo, P.E., Marinelli, G., Pavese, F., Iacono, A. (2001) Dilated cardiomyopathy in dialysis patients: beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol, 37(2): 407-11
Cice, G., Ferrara, L., Andrea, A.D., Isa, S.D., di Benedetto, A., Cittadini, A., Russo, P.E., Golino, P., Calabrò, R. (2003) Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol, 41(9): 1438-44
Cohen-Solal, A. (1998) Left ventricular diastolic dysfunction: pathophysiology, diagnosis and treatment. Nephrol Dial Transplant, 13(suppl 4)
David, S., Kümpers, P., Seidler, V., Biertz, F., Haller, H., Fliser, D. (2008) Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant, 23(4): 1370-7
de Bie, M.K., Buiten, M.S., Rabelink, T.J., Jukema, W.J. (2012) How to reduce sudden cardiac death in patients with renal failure. Heart, 98(4): 335-41
Flythe, J.E., Brunelli, S.M. (2011) The risks of high ultrafiltration rate in chronic hemodialysis: implications for patient care. Semin Dial, 24(3): 259-65
Furgeson, S.B., Chonchol, M. (2008) Beta-blockade in chronic dialysis patients. Semin Dial, 21(1): 43-8
Green, D., Roberts, P.R., New, D.I., Kalra, P.A. (2011) Sudden Cardiac Death in Hemodialysis Patients: An In-Depth Review. Am J Kidney Dis, 57(6): 921
Gussak, I., Gussak, H.M. (2007) Sudden cardiac death in nephrology: focus on acquired long QT syndrome. Nephrol Dial Transplant, 22(1): 12-4
Hamlin, S.K., Villars, P.S., Kanusky, J.T., Shaw, A.D. (2004) Role of diastole in left ventricular function, II: diagnosis and treatment. Am J Crit Care, 13(6): 453-66; quiz 467-8
Herzog, C.A. (2007) Can we prevent sudden cardiac death in dialysis patients?. Clin J Am Soc Nephrol, 2(3): 410-2
Herzog, C.A., Mangrum, M.J., Passman, R. (2008) Sudden cardiac death and dialysis patients. Semin Dial, 21(4): 300-7
Ie, E.H.Y., Zietse, R. (2006) Evaluation of cardiac function in the dialysis patient: a primer for the non-expert. Nephrol Dial Transplant, 21(6): 1474-81
Ito, I., Kono, K., Shinbo, G., Tadokoro, K., Abe, C., Takemura, N., i dr. (2009) Implantable cardioverter defibrillator in maintenance hemodialysis patients with ventricular tachyarrhythmias: A single-center experience. Hemodialysis Int, 13(1): 48
Johnston, N., Dargie, H., Jardine, A. (2008) Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease: Ischaemic heart disease. Heart, 94(8): 1080-8
Kanbay, M., Solak, Y., Covic, A., Goldsmith, D. (2011) Sudden cardiac death in patients with chronic kidney disease: prevention is the sine qua non. Kidney Blood Press Res, 34(4): 269-76
Kanbay, M., Afsar, B., Goldsmith, D., Covic, A. (2010) Sudden death in hemodialysis: an update. Blood Purif, 30(2): 135-45
Korantzopoulos, P., Liu, T., Li, L., Goudevenos, J.A., Li, G. (2009) Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. Europace, 11(11): 1469-75
London, G.M., Guerin, A.P., Marchais, S.J. (1999) Hemodynamic Overload in End-Stage Renal Disease Patients. Semin Dial, 12(2): 77
London, G.M. (2003) Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial, 16(2): 85-94
Maisel, A.S., Katz, N., Hillege, H.L., Shaw, A., Zanco, P., Bellomo, R., Anand, I., Anker, S.D., Aspromonte, N., Bagshaw, S.M., Berl, T., Bobek, I. (2011) Biomarkers in kidney and heart disease. Nephrol Dial Transplant, 26(1): 62-74
Massy, Z.A., Kasiske, B.L. (2000) Prevention of cardiovascular complications in chronic renal disease. u: Loscalzo J., London G.M. [ur.] Cardiovascular Disease in End-stage Renal Failure, New York: The Oxford University Press, : 463-81
McCullough, P.A., Sandberg, K.R. (2004) Chronic kidney disease and sudden death: strategies for prevention. Blood Purif, 22(1): 136-42
McMahon, L.P., Roger, S.D., Levin, A. (2004) Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol, 15(6): 1640-7
McQuillan, R.F., Chan, C.T. (2012) The intuitive case for β-blockers in patients with ESRD. Semin Dial, 25(1): 15-21
Middleton, R.J., Parfrey, P.S., Foley, R.N. (2001) Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol, 12(5): 1079-84
Middleton, R.J., Parfrey, P.S., Foley, R.N. (2001) Left Ventricular Hypertrophy in the Renal Patient. J Am Soc Nephrol, 12(5): 107
Nevis, I.F., Mathew, A., Novick, R.J., Parikh, C.R., Devereaux, P.J., Natarajan, M.K., Iansavichus, A.V., Cuerden, M.S., Garg, A.X. (2009) Optimal method of coronary revascularization in patients receiving dialysis: systematic review. Clin J Am Soc Nephrol, 4(2): 369-78
Parfrey, P.S., Collingwood, P., Foley, R.N., Bährle, A. (1996) Images in nephrology. Left ventricular disorders detected by M-mode echocardiography in chronic uraemia. Nephrol Dial Transplant, 11(7): 1328-31
Parfrey, P.S. (2000) Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant, 15(suppl 5)
Pecoits-Filho, R., Bucharles, S., Barberato, S.H. (2012) Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment. Semin Dial, 25(1): 35-41
Petrović, D. (2012) Srčana slabost kod bolesnika na hemodijalizi. u: Petrović D. [ur.] Kardiovaskularne bolesti kod bolesnika na hemodijalizi, Kragujevac: Medicinski fakultet i Inter Print, : 271-88
Petrović, D., Tirmenštajn-Janković, B., Živanović, M., Nikolić, A., Poskurica, M., Stojimirović, B. (2010) Iznenadna srčana smrt kod bolesnika koji se leče redovnim hemodijalizama. Timočki medicinski glasnik, vol. 35, br. 1-2, str. 19-26
Petrović, D., Obrenović, R., Stojimirović, B. (2008) Cardiac troponins and left ventricular hypertrophy in hemodialysis patients. Clin Lab, 54(5-6): 145-52
Petrović, D., Jagić, N., Miloradović, V., Stojimirović, B. (2008) Clinical importance of biochemical markers of cardiac damage in hemodialysis patients. Serbian Journal of Experimental and Clinical Research, vol. 9, br. 1, str. 19-25
Petrović, D., Stojimirović, B.B. (2009) Cardiac troponins: outcome predictors in hemodialysis patients. J Artif Organs, 12(4): 258-63
Petrović, D., Miloradović, V., Poskurica, M., Stojimirović, B. (2011) Heart failure in haemodialysis patients: Evaluation and treatment. Srpski arhiv za celokupno lekarstvo, vol. 139, br. 3-4, str. 248-255
Petrović, D., Stojimirović, B. (2008) Hipertrofija leve komore kod bolesnika koji se leče redovnim hemodijalizama. Medicinski pregled, vol. 61, br. 7-8, str. 369-374
Petrović, D., Stojimirović, B. (2007) Protok krvi kroz vaskularni pristup za hemodijalizu - faktor rizika za razvoj kardiovaskularnih komplikacija kod bolesnika na hemodijalizi. Medicinski pregled, vol. 60, br. 3-4, str. 183-186
Petrović, D., Poskurica, M., Stojimirović, B. (2011) Hipertrofija leve komore kod bolesnika na hemodijalizi - faktori rizika i lečenje. Medicinska istraživanja, vol. 45, br. 3, str. 30-35
Petrović, D., Jagić, N., Miloradović, V., Nikolić, A., Stojimirović, B. (2011) Diagnostics and therapy of left ventricular hypertrophy in haemodialysis patients. Serbian Journal of Experimental and Clinical Research, vol. 12, br. 1, str. 37-40
Postorino, M., Marino, C., Tripepi, G., Zoccali, C. (2007) Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrol Dial Transplant, 22(5): 1377-82
Ranpuria, R., Hall, M., Chan, C.T., Unruh, M. (2008) Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrol Dial Transplant, 23(2): 444-9
Rigatto, C., Parfrey, P.S. (2001) Uraemic Cardiomyopathy: an Overload Cardiomyopathy. J Clin Basic Cardiol, 4(2): 93-9
Roberts, J.K., Patel, U.D. (2011) Management of coronary artery disease in end-stage renal disease. Semin Dial, 24(5): 525-32
Roberts, P.R., Green, D. (2011) Arrhythmias in chronic kidney disease. Heart, 97(9): 766-73
Shamseddin, K.M., Parfrey, P.S. (2011) Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol, 7(3): 145-54
Sood, M.M., Pauly, R.P., Rigatto, C., Komenda, P. (2008) Left ventricular dysfunction in the haemodialysis population. NDT Plus, 1(4): 199-205
Stojimirović, B., Petrović, D., Obrenović, R. (2007) Hipertrofija leve komore kod bolesnika na hemodijalizi: značaj anemije. Med Pregl, 60(suppl 2)
Wang, A.Y., Sanderson, J.E. (2011) Current perspectives on diagnosis of heart failure in long-term dialysis patients. Am J Kidney Dis, 57(2): 308-19
Williams, M.E. (2006) Coronary revascularization in diabetic chronic kidney disease/end-stage renal disease: a nephrologist's perspective. Clin J Am Soc Nephrol, 1(2): 209-20
Wu, V., Lin, L., Wu, K. (2005) QT interval dispersion in dialysis patients. Nephrology (Carlton), 10(2): 109-12